18 Alendronate to denosumab in OVX monkeys Transition from alendronate to denosumab further reduced biochemical markers of bone turnover Vehicle -Vehicle Vehicle -Dmab Resorption marker ALN -ALN Formation marker ALN -Dmab Dmab -Dmab 4 160 140 3 120 100 Serum CTx (ng/ml) Serum BSAP (U/L) * ^ * 2 80 * 60 * ^ * 1 40 * ^ ^ * * ^ 20 * ^ * ^ 3 6 9 12 3 6 9 12 Treatment (months) Treatment (months) *p < 0.05 vs vehicle ^p < 0.05 vs ALN Ominsky MS, et al.